Fresenius Medical Care AG (FMCQF)
| Previous close | 38.10 |
| Open | 38.10 |
| Bid | 39.25 x 27000 |
| Ask | 41.80 x 27000 |
| Day's range | 38.10 - 38.10 |
| 52-week range | 34.33 - 47.05 |
| Volume | |
| Avg. volume | 353 |
| Market cap | 11.693B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | 19.32 |
| EPS (TTM) | 2.01 |
| Earnings date | 05 Nov 2024 |
| Forward dividend & yield | 1.29 (3.33%) |
| Ex-dividend date | 17 May 2024 |
| 1y target est | N/A |
ZacksFresenius Medical Care Stock Rises on NxStage VersiHD Launch
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
PR NewswireFresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software
Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis (HHD) therapy through both Fresenius Kidney Care clinics and other providers. The company has in parallel launched the newest version of its home dialysis machine, the NxStage® Versi®HD with GuideMe Software, featuring enhancements designed to simplify treatment, increase ease of learning, and improv
ZacksReasons to Retain Fresenius Medical Stock in Your Portfolio Now
FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
